Shares of Amgen Inc. AMGN advanced 1.24% to $297.93 Thursday, on what proved to be an all-around dismal trading session for ...

Amgen's AMGN short percent of float has risen 11.27% since its last report. The company recently reported that it has 12.74 million shares sold short, which is 2.37% of all regular shares that are ...

Citi analyst Geoff Meacham maintained a Hold rating on Amgen (AMGN – Research Report) today and set a price target of $295.00. The company’s ...

People who have trouble breathing as they sleep often turn to ResMed, which makes a face-worn breathing apparatus. Its ...

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The ...

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research led by investigators at the Johns Hopkins Kimmel ...

Amgen (NASDAQ:AMGN – Get Free Report) had its target price raised by Bank of America from $256.00 to $275.00 in a report issued on Thursday,Benzinga reports. The firm currently has an “underperform” ...

Shares of Amgen Inc. AMGN shed 1.42% to $293.54 Friday, on what proved to be an all-around dismal trading session for the ...

All of a sudden, Amgen stock is up 15% since late December to around $299. Its rise helped push up the healthcare sector up just over 7% since hitting a bottom in late December. The better-than ...

Naturally, there will be many readers out there who continue to view MariTide as a major catalyst for upside, and I'd agree that anyone holding Amgen stock may regret selling its stock today.